Financing the human papillomavirus (HPV) vaccine and mobilizing resources to support new delivery mechanisms will constitute some of the most significant challenges to achieving widespread HPV vaccination in the developing world. Country decision-makers will need to weigh the value of HPV vaccines against other national health priorities, against other vaccines entering the market, and, for some countries, against expanding coverage of existing vaccines. With these cost and financing obstacles resolved, developing countries would be able to build robust programs to immunize adolescents and thus dramatically reduce the incidence of cervical cancer.
Corporate author(s): PATH and International AIDS Vaccine Initiative (IAVI)
Publication date: December 2007
(Located at www.rho.org)
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA